Please ensure Javascript is enabled for purposes of website accessibility

Why BioNTech Fell by 7% Today Before Recovering

By Eric Volkman - Apr 26, 2021 at 6:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There was encouraging news for rival coronavirus vaccine developers on and just before Monday.

What happened

Shares of BioNTech (BNTX -0.52%) stumbled early on Monday, falling by as much as 6.6% before recovering. The stock closed the day slightly above water, with a gain of just under 1%.

So what

BioNTech didn't report any significant news. The early Monday slide seems to have more to do with developments reported about other coronavirus vaccine developers than any internal factor.

Just before the start of last weekend, both the FDA and the Centers for Disease Control and Prevention lifted their pause on use of Johnson & Johnson's (JNJ 0.09%) coronavirus vaccine.

Man receiving a vaccination shot.

Image source: Getty Images.

Johnson & Johnson's jab has one significant advantage over both BioNTech and Pfizer's BNT162b2 and Moderna's (MRNA 2.58%) mRNA-1273 -- it is a single-shot vaccine. As such it's a compelling option in this country, where the aim is to get as many shots in arms as quickly as possible.

Speaking of Moderna, on Monday the biotech announced it struck a deal with international peer Sanofi for the latter to provide fill/finish manufacturing services and packaging for as many as 200 million doses of mRNA-1273, starting this September. That assistance will be a real boost to the company's supply in the final months of this year.

Now what

Yet BioNTech/Pfizer's shot is still a default option not only in the U.S., but also in other big markets around the world. It's got a very bright future, as do messenger RNA-based vaccines more broadly. No investor should worry about BioNTech's early Monday stock weakness.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$160.20 (-0.52%) $0.83
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.75 (2.15%) $1.11
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.30 (0.09%) $0.16
Sanofi Stock Quote
Sanofi
SNY
$50.04 (-0.28%) $0.14
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$159.56 (2.58%) $4.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.